ITM Isotopen Technologien München AG is a privately held group of biotechnology and radiopharmaceutical companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Since its founding in 2004, ITM and its subsidiaries have established GMP production and a robust global supply network of innovative, best-in-class medical radioisotopes and generator platforms for the next generation of targeted cancer diagnostics and therapies.
In addition, ITM is developing a proprietary portfolio and expanding its oncology product range, which includes targeted therapies at various stages of clinical development for a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α-positive tumors such as lung, ovarian or breast cancer.
At Nukleon, we serve as the authorized distributor in the Turkish market for ITM’s high-yield nonGMP or GMP grade Ge-68/Ga-68 Generator, the highly pure and carrier-free EndolucinBeta® (n.c.a. Lutetium-177), the user-friendly iQS-TS synthesis device that completes the synthesis process in a total of 17 minutes including elution, and all related accessories.
For more information, you can visit itm.ag ↗.